FORTECORTIN 4MG Tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

fortecortin 4mg tableta

merck spol. s r.o., praha array - 451 dexamethason - tableta - 4mg - dexamethason

Dexashot 2 mg/ml Injekční roztok Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

dexashot 2 mg/ml injekční roztok

vet-agro multi-trade company sp. z o.o. - dexamethason - injekční roztok - glukokortikoidy - skot, prasata, koně, kočky, psi

Dexacortone 0,5 mg 0,5 mg Žvýkací tableta Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

dexacortone 0,5 mg 0,5 mg Žvýkací tableta

le vet beheer, b.v. - dexamethason - Žvýkací tableta - glukokortikoidy - psi, kočky

Dexacortone 2 mg 2 mg Žvýkací tableta Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

dexacortone 2 mg 2 mg Žvýkací tableta

le vet beheer, b.v. - dexamethason - Žvýkací tableta - glukokortikoidy - psi, kočky

RAPIDEXON 2 mg/ml Injekční roztok Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

rapidexon 2 mg/ml injekční roztok

eurovet animal health, b.v. - dexamethason - injekční roztok - 2mg/ml - glukokortikoidy - kočky, koně, prasata, skot, psi

OTOSPECTRINE Ušní kapky, suspenze Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

otospectrine ušní kapky, suspenze

base pharmaceuticals b.v. - dexamethason a antiinfectives - ušní kapky, suspenze - kortikosteroidy a antiinfectives v kombinaci - psi, kočky

PRURIVET N Kožní roztok Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

prurivet n kožní roztok

vetoquinol s.r.o. - dexamethason a antibiotika - kožní roztok - kortikosteroidy, středně silný, kombinace s antibiotiky - psi

SPERSADEX COMP. 5MG/ML+1MG/ML Oční kapky, roztok Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

spersadex comp. 5mg/ml+1mg/ml oční kapky, roztok

laboratoires thea, clermont-ferrand array - 297 chloramfenikol; 453 sodnÁ sŮl dexamethason-fosfÁtu - oční kapky, roztok - 5mg/ml+1mg/ml - dexamethason a antiinfektiva

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Evropská unie - čeština - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresiva - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Evropská unie - čeština - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).